



The antiphospholipid syndrome: still an enigma

Shruti Chaturvedi¹ and Keith R. McCrae²

¹Division of Hematology, Vanderbilt University Medical Center, Nashville, TN; and ²Hematology and Solid Tumor Oncology, Cleveland Clinic, Cleveland, OH

Antiphospholipid syndrome (APS) is defined by clinical manifestations that include thrombosis and/or fetal loss or pregnancy morbidity in patients with antiphospholipid antibodies (aPL). Antiphospholipid antibodies are among the most common causes of acquired thrombophilia, but unlike most of the genetic thrombophilias are associated with both venous and arterial thrombosis. Despite an abundance of clinical and basic research on aPL, a unified mechanism that explains their prothrombotic activity has not been defined; this may reflect the heterogeneity of aPL and/or the fact that they may influence multiple pro- and/or antithrombotic pathways. Antiphospholipid antibodies are directed primarily toward phospholipid binding proteins rather than phospholipid per se, with the most common antigenic target being β_2 -glycoprotein 1 (β_2 GPI) although antibodies against other targets such as prothrombin are well described. Laboratory diagnosis of aPL depends upon the detection of a lupus anticoagulant (LA), which prolongs phospholipid-dependent anticoagulation tests, and/or anticardiolipin and anti- β_2 -glycoprotein 1 antibodies. Indefinite anticoagulation remains the mainstay of therapy for thrombotic APS, although new strategies that may improve outcomes are emerging. Preliminary reports suggest caution in the use of direct oral anticoagulants in patients with APS-associated thrombosis. Based on somewhat limited evidence, aspirin and low molecular weight heparin are recommended for obstetrical APS. There remains a pressing need for better understanding of the pathogenesis of APS in humans, for identification of clinical and laboratory parameters that define patients at greatest risk for APS-related events, and for targeted treatment of this common yet enigmatic disorder.

Learning Objectives

- To review the definition of antiphospholipid antibody syndrome (APS) and its relevance to clinical manifestations in patients with antiphospholipid antibodies
- To discuss selected aspects of APS pathogenesis and how they may impact targeted therapies
- To review current recommendations for treatment of thrombotic and obstetric APS

The antiphospholipid syndrome (APS) is characterized by arterial or venous thrombosis and/or pregnancy morbidity accompanied by persistently positive tests for antiphospholipid antibodies (aPL).¹ The deep veins of the lower extremities and the cerebral circulation are the most common sites of venous and arterial thrombosis, respectively.² Obstetrical morbidity includes both recurrent early, or a single late (beyond 10 weeks) pregnancy loss and/or premature birth associated with preeclampsia and placental insufficiency.¹ A severe form of APS termed catastrophic antiphospholipid syndrome (CAPS) occurs in <1% patients with aPL,¹ and is defined as thrombosis affecting 3 or more organs within a period of 1 week with histologic confirmation of small vessel thrombosis.³ CAPS has a mortality rate of 33%-50%, mostly due to cerebral and cardiac thrombosis, or renal failure.⁴⁻⁶ Patients with APS may also demonstrate thrombocytopenia, livedo reticularis, skin ulcers, valvular heart disease, and transient ischemic attacks.⁴ Although these are

considered “non-criteria” manifestations of APS, their presence along with thrombosis or pregnancy loss, should alert clinicians to this diagnosis.

Pathogenesis of APS

Though originally thought to react with anionic or polar phospholipids, such as cardiolipin, subsequent studies demonstrated that most aPL are directed against phospholipid binding proteins. β_2 GPI is the primary antigenic target of aPL, although many other antigenic targets, such as prothrombin, have been described.^{7,8} β_2 GPI is comprised of 5 “sushi” domains, the fifth domain being atypical and mediating binding to anionic phospholipid, while pathologic anti- β_2 GPI antibodies have been reported to bind primarily to domain 1.⁹ β_2 GPI has been proposed to circulate in a “circular” conformation in which interactions between domains 1 and 5 result in shielding of the domain 1 epitope (Figure 1); this may account for the absence of circulating β_2 GPI-containing immune complexes in patients with aPL.¹⁰ Unfolding of β_2 GPI with assumption of a “fishhook” conformation is presumed to occur upon binding to phospholipid or cellular receptors, exposing the antigenic region in domain 1.

Anti- β_2 GPI antibodies are central to the pathogenesis of APS, and recognize β_2 GPI bound to the surface of endothelial cells, monocytes, and immobilized platelets, in some cases leading to cellular activation and expression of procoagulant activity.¹¹ Human anti- β_2 GPI autoantibodies potentiate arterial and venous thrombus formation in a mouse model,¹¹ and lupus anticoagulants whose

Conflict-of-interest disclosure: The authors declare no competing financial interests.

Off-label drug use: Rituximab.




Figure 1. Proposed structures of the open and closed forms of β_2 GPI DI-DV represent the 5 domains of β_2 GPI. (A) β_2 GPI structure in the “open” form, as identified by its crystal structure. In this conformation, often referred to the “fish hook” conformation, an epitope containing Lys19, Arg39, and Arg43 that is recognized by anti- β_2 GPI domain 1 antibodies is exposed. β_2 GPI incubated at high pH adopts this conformation, and it is proposed that binding of anionic phospholipid results in similar conformational changes. (B) The “circular” form of β_2 GPI. This conformation is suggested by electron microscopy of circulating plasma β_2 GPI. In this conformation, the epitopes recognized by anti- β_2 GPI domain 1 antibodies are not available, which is thought to explain the fact that circulating immune complexes are not present in patients with antiphospholipid antibodies. This conformation is proposed to be maintained by interactions between domain 1 and domain 5. Reprinted with permission from Agar et al.¹⁰

effects are mediated via interactions with β_2 GPI, or anti- β_2 GPI antibodies, are associated with a higher risk of thrombosis than anticardiolipin (aCL) or anti-prothrombin antibodies.^{7,12} Other mechanisms by which aPL have been proposed to effect a hypercoagulable state include inhibition of the anticoagulant activity of

protein C and S, disruption of the annexin A5 shield on cell surfaces,¹³ inhibition of the ability of β_2 GPI to inhibit VWF-dependent platelet aggregation,¹⁴ and complement activation.¹⁵ Anti- β_2 GPI antibody binding to β_2 GPI on placental trophoblasts results in inhibition of growth and differentiation, and in animal models causes tissue factor and complement-mediated neutrophil activation, trophoblast injury, and fetal loss.¹⁶

Diagnosis of APS

The Sapporo criteria, the first consensus criteria for the diagnosis of “definite APS,” were proposed in 1999, and updated in 2006 after a conference in Sydney, Australia.¹ These include both clinical and laboratory criteria, and diagnosis rests on the presence of at least one of each. Clinical criteria include either objectively confirmed venous, arterial, or small vessel thrombosis, or obstetric morbidity including the unexplained death of one or more morphologically normal fetuses at or beyond the 10th week of gestation, the premature birth of 1 or more morphologically normal neonates before the 34th week of gestation, and/or 3 or more unexplained, consecutive spontaneous abortions before the 10th week of gestation (Table 1).¹ The laboratory criteria require demonstration of a persistent lupus anticoagulant detected according to guidelines published by the ISTH (Table 2),¹⁷ aCL antibody (IgG or IgM) exceeding 40 IgG or IgM antiphospholipid units, or anti- β_2 GPI antibody (IgG or IgM) at levels exceeding the 99th percentile.¹ These three laboratory tests detect antibodies with overlapping, but not always identical specificity. These criteria were proposed to standardize the diagnosis of APS and aPL for clinical trials, however, they have several shortcomings in practice. For example, patients with “non-criteria” manifestations other than thrombosis or pregnancy morbidity, and those with thrombosis but only low-to-moderate titers of anti- β_2 GPI and ACL are not formally recognized as having APS. The clinical implications of IgA aCL or anti- β_2 GPI

Table 1. Summary of the Sydney Consensus Statement on Classification of APS

Antiphospholipid antibody syndrome (APS) is present if at least one of the clinical criteria and one of the laboratory criteria are met	
Clinical criteria	
1. Vascular thrombosis	One or more documented episodes of arterial, venous, or small vessel thrombosis in any tissue. Thrombosis must be confirmed by objective validated criteria. For histologic confirmation, thrombosis should be present without significant vessel wall inflammation.
2. Pregnancy morbidity	<ul style="list-style-type: none"> a. One or more unexplained deaths of a morphologically normal fetus at or beyond the 10th week of gestation, with normal fetal morphology documented by ultrasound or direct examination of the fetus, or b. One or more premature births of a morphologically normal neonate before the 34th week of gestation because of eclampsia or preeclampsia diagnosed by standard definitions, or recognized features of placental insufficiency, or c. Three or more unexplained consecutive spontaneous abortions before the 10th week of gestation, with maternal or hormonal abnormalities, and maternal and paternal chromosomal causes excluded.
Investigators are strongly advised to classify subjects with obstetrical morbidity according to groups a, b, and c in populations of patients with more than one type of pregnancy morbidity.	
Laboratory criteria	
1. Lupus anticoagulant (LA) present in plasma, on 2 or more occasions at least 12 weeks apart, detected according to the guidelines of the International Society of Thrombosis and Hemostasis.	
2. Anticardiolipin antibody (aCL) of IgG and/or IgM isotype in serum or plasma, present in medium or high titer (>40 GPL or MPL, or >99th percentile), on 2 or more occasions, at least 12 weeks apart, measured by a standardized ELISA.	
3. Anti- β_2 glycoprotein-I antibody (anti- β_2 GPI) of IgG and/or IgM isotype in serum or plasma with a titer >99th percentile, on 2 or more occasions, at least 12 weeks apart, measured by a standardized ELISA.	
Investigators are strongly urged to classify APS patients into one of the following categories:	
I: >1 laboratory criteria present (any combination)	
IIa: LA present alone	
IIb: aCL present alone	
IIc: anti- β_2 GPI present alone	

Modified from Miyakis et al.¹

Table 2. ISTH criteria for diagnosis of lupus anticoagulants**Positive screening test (phospholipid-dependent coagulation assay)**

Two or more screening tests recommended: dilute Russell's viper venom time (DRVVT) and a sensitive aPTT (low phospholipids with silica as activator)

Evidence of inhibition in mixing studies (exclude factor deficiency)

1:1 mixing of patient plasma with normal plasma does not correct the prolonged clotting time

LA cannot be conclusively identified if thrombin time is prolonged

Evidence that inhibition is phospholipid-dependent

Confirmatory test(s) performed by performing tests in which increased phospholipid corrects or reduces the prolonged clotting time

Examples: DRVVT confirm, hexagonal phase phospholipid, platelet neutralization test, others

Exclusion of coagulation inhibitors

Heparin

Direct thrombin or factor Xa inhibitors (DOAC)

Coagulation factor inhibitors (eg, factor VIII inhibitor)

Modified from Pengo et al.¹⁷

antibodies, and aPL directed against antigens such as phosphatidylserine or phosphatidylethanolamine remain controversial and routine testing for these is not recommended.

Laboratory investigation is central to the diagnosis of APS. Unfortunately, aPL assays, particularly solid-phase assays for anti- β_2 GPI and aCL antibodies, are plagued by substantial interlaboratory variability.^{7,18} Patient factors also affect testing. For example, false-positive LA assays may result from anticoagulation with heparins or direct oral anticoagulants (DOACs).^{19,20} Martinuzzo et al studied patients on rivaroxaban, dabigatran, or LMWH, who had tested negative for lupus anticoagulant at baseline. Samples were drawn 4 hours after administration of enoxaparin and between 1.5 and 4 hours after taking enoxaparin or dabigatran. Nearly all patients taking dabigatran had prolongation of the activated partial thromboplastin time (APTT), silica clotting time (SCT), and dilute Russell's viper venom time (DRVVT). There was also a high prevalence of DRVVT prolongation (81%-100%) with LMWH, whereas prolongation of the APTT and SCT was less common (13%-100% depending on dose).²¹ Though warfarin prolongs clotting times, its effect on clotting time ratios in LA assays is variable. The uncertainty concerning this conundrum is reflected in discrepant recommendations within different guidelines.²² Many authors advocate performance of LA studies using a 1:1 mix of patient and normal plasma, to reduce the effects of warfarin-induced reduction in clotting factor levels on LA testing. Others have found that certain venoms, for example Taipan snake venom, is a more "LA-specific" reagent that can be used for LA diagnosis even in the presence of warfarin or rivaroxaban; however, these tests are not widely available.^{23,24}

A positive LA test may be caused by aPL directed against β_2 GPI, prothrombin or other less commonly identified antigens. LA whose effects are mediated via interactions with β_2 GPI confer a higher risk of thrombosis than those due to anti-prothrombin antibodies,^{7,12,25} although it has been suggested that antibodies to phosphatidylserine-prothrombin complexes may detect a subtype of antibodies more closely associated with thrombosis than those against prothrombin alone.⁸ In a recent study, the presence of a β_2 GPI dependent LA was strongly associated with thrombosis [odds ratio (OR) 42.3; 95% confidence interval (CI) 9.9-194.3], whereas there was no increased frequency of thrombosis in a group of 33 patients with non- β_2 GPI dependent LA (OR 1.6; 95%CI 0.8-3.9).²⁶ Discriminating anti- β_2 GPI-dependent and independent aCL and LA may have important implications for identifying high-risk patients, although these studies are not commonly available in practice.

A disorder with clinical manifestations of APS but lacking positivity in any of the standard diagnostic laboratory studies has been termed "seronegative APS." The relationship of this disorder to APS is uncertain.

Assessment of thrombotic risk

Despite advances in understanding the pathologic processes underlying APS, the ability to identify individuals at greatest risk of thrombosis remains challenging. It is particularly difficult to predict the risk of first thrombosis in asymptomatic aPL carriers.

aPL profile and thrombotic risk

LA positivity is a stronger risk factor for both arterial and venous thrombosis than anticardiolipin antibodies.⁶ However, there is a significant variation in strength of association in different studies that may reflect different methods used to detect LA, or the variable inclusion of LA that were not persistently positive.¹² Retrospective and prospective studies have shown no consistent association between thrombosis and aCL.^{7,27} Because β_2 GPI is the primary antigen in APS, the anti- β_2 GPI antibody has been proposed as the more clinically significant and predictive aPL. Several retrospective studies showed that anti- β_2 GPI antibodies indeed correlate with thrombotic risk,²⁸⁻³⁰ although these results have not been universally confirmed and recent studies suggest that the thrombotic risk conferred by anti- β_2 GPI antibodies is modest, with odds ratios between 1.5 and 2.5.²⁸

Based on reports demonstrating that positivity for 2 or more LA, aCL, and/or anti- β_2 GPI antibodies is more strongly associated with thrombosis and may be useful in assessing thrombotic risk. The updated Sydney criteria advise classification of patients into those with positivity for 1, 2, or all 3 "criteria" aPL (Table 1). For example, data from the Warfarin in Antiphospholipid Syndrome (WAPS) study showed that patients with LA and anti- β_2 GPI antibodies had a significantly increased risk for thrombosis (OR 4.1, 95% CI 1.3-13.5).⁷ Pengo et al reported a cumulative incidence of recurrent thrombosis of 12.2%, 26.1%, and 44.2% after 1, 5, and 10 years of follow-up in a retrospective analysis of 160 APS patients positive for LA, aCL, and anti- β_2 GPI—so-called "triple-positive" patients—123 of whom were on long-term anticoagulation.³¹ Similarly, in a recent study of 119 female aPL carriers, the annual rate of a first thrombotic event in individuals with double- or triple-positivity (1.27%) was twice as high as that in women with single-positivity (0.65%).³²

Recent reports suggest that IgG anti- β_2 GPI-domain1 antibodies are more strongly associated with a history of thrombosis and obstetrical

morbidity compared to antibodies to other regions of the protein.^{33,34} A prospective study reported that IgG anti- β_2 GPI domain 1 antibodies were more often persistent at 12 weeks, associated with triple-positivity, and correlated with thrombotic risk.³⁵ Commercial assays for domain 1 antibodies are in development.

How to treat asymptomatic patients with positive aPL is a challenging question for which little evidence-based guidance is available, and is discussed in the “How I treat” section.

Other considerations

Persistence and high levels of aPL are associated with an increased risk of thrombosis.¹ The presence of systemic lupus erythematosus (SLE), and other thrombotic risk factors, such as inherited thrombophilia, cancer, immobilization, smoking, pregnancy, and the use of oral contraceptives, and previous thrombosis also increase thrombotic risk.

Obstetrical APS

The literature addressing the association of aPL with obstetrical complications is confounded by different definitions of recurrent fetal loss and aPL positivity, as well as the heterogeneity of aPL assays performed in different labs. Clark et al demonstrated persistently positive lupus anticoagulants in 2.7% of women with recurrent pregnancy loss.³⁶ The presence of LA correlated with thromboembolism during pregnancy, ≥ 1 stillbirth (beyond 32 weeks), intrauterine growth retardation, and the HELLP syndrome, but not with ≥ 2 spontaneous abortions (≤ 12 weeks). The PROMISSE study examined the correlation of LA and aCL with poor pregnancy outcomes, observing that positivity for LA was most strongly associated, with aCL >40 IgG phospholipid (GPL) units less strongly, but still significantly associated.³⁷ However, most patients with positive aCL and poor outcomes also had positive LA. The Nimes Obstetrician and Haematologists Cohort Study, a large prospective study analyzing an initial cohort of more than 32 000 primigravidae, confirmed a significant association of LA, aCL or the combination with early pregnancy loss, although only LA were associated with preeclampsia.³⁸

Treatment of thrombosis in APS

Long-term anticoagulation with a vitamin K antagonist (VKA) is the mainstay of therapy for thrombotic APS. However, a significant proportion of patients have recurrent thrombosis despite therapeutic anticoagulation,^{4,31} and patients with aPL and thrombosis are at higher risk for subsequent cardiovascular mortality than those without. Further complicating treatment is the fact that patients with aPL may be at higher risk of bleeding because of thrombocytopenia or other comorbidities.

Venous thrombotic events

Anticoagulation with unfractionated heparin or low molecular weight heparin transitioned to a VKA, most commonly warfarin, is the standard treatment for a first venous thrombotic event. A target INR of 2.5 (2.0-3.0) is recommended. Given the high rate of recurrent thrombosis in APS, two randomized trials compared standard intensity (INR 2.0-3.0) versus high intensity (INR 3.0-4.0) anticoagulation with warfarin in patients with APS but found no difference in the rates of recurrent thrombosis or major bleeding, supporting the use of standard intensity anticoagulation.^{39,40} The optimal duration of anticoagulation is unclear, however given that recurrence rates as high as 19%-29% have been reported in patients not receiving long-term anticoagulation, it is recommended that treatment be continued indefinitely. In a recent systematic review of

8 prospective studies, Garcia et al reported that patients with aPL had a higher rate of recurrent thrombosis after stopping anticoagulation with a relative risk of 1.41 (95% CI 0.99-2.00).⁴¹ The fact that the confidence interval included “no effect” questions the need for indefinite anticoagulation. However, the studies analyzed were of limited methodologic quality, and most patients did not have confirmed APS. Hence, as in any patient with thrombosis, the duration of anticoagulation must be determined based upon the risk-benefit ratio of the individual patients, taking into account not only the risk of recurrent thrombosis, but the likelihood of bleeding, falls and compliance. Short-term anticoagulation may be considered in patients who develop thrombosis in the setting of a reversible risk factor, and those who subsequently test negative for aPL. Also, children with APS have a lower risk of recurrent thrombosis compared with adults and may not need long-term anticoagulation.⁴²

Arterial thrombosis

In the Antiphospholipid Antibodies and Stroke (APASS) study, a subgroup of the Warfarin-Aspirin Recurrent Stroke Study (WARSS) that compared warfarin versus aspirin for secondary stroke prevention, no association was observed between aPL positivity and recurrent stroke, and there was no difference between the rate of recurrent stroke in the warfarin (INR 1.4-2.8) and aspirin groups.⁴³ However, the results from this study are not generalizable to all patients with APS and stroke, because aPL were tested only once at baseline, low-positive anticardiolipin antibodies were included, and several patients had other cardiovascular risk factors. Other than one small randomized trial that reported lower rates of recurrent stroke in patients treated with aspirin plus warfarin versus aspirin alone,⁴⁴ there are no prospective trials of secondary stroke prevention in APS. Patients with APS and non-stroke arterial events are frequently treated with combination antiplatelet and anticoagulant therapy, continued indefinitely. There is currently no consensus on the use of high-intensity anticoagulation for the secondary prophylaxis of arterial thrombosis. This may be considered, however, in APS patients with a high-risk aPL profile and other cardiovascular risk factors if the potential benefit outweighs the risk of bleeding.

The direct oral anticoagulants (DOACs)

The use of VKAs may be problematic in some patients because of food and drug interactions, bleeding complications, and need for frequent monitoring. Also, aPL differentially affect thromboplastin reagents, potentially affecting the international normalized ratio. DOACs have the potential to overcome some of these issues; they are fixed-dose, do not need routine monitoring, and are effective in the treatment of venous thrombosis in unselected individuals. However, there is limited experience with these agents in patients with APS. Three recent case series, comprising 18 patients in all, reported recurrent thrombosis in 8 of 18 individuals, suggesting caution when considering the use of DOACs in patients with APS.⁴⁵⁻⁴⁷ The Rivaroxaban in Thrombotic AntiPhospholipid Syndrome (TRAPS) trial (www.clinicaltrials.gov; NCT02157272) is an open-label, prospective, non-inferiority randomized trial evaluating the efficacy of rivaroxaban in patients with thrombotic APS, and is currently open. Results of this study should provide definitive insight into the role of DOACs in APS. However, in the absence of prospective data, DOACs should be used cautiously in these patients, and limited to individuals who either fail or are intolerant of a VKA or low molecular weight heparin.

Non-anticoagulant treatment of thrombotic APS

Advances in the understanding of pathogenic mechanisms involved in APS have led to the identification of new therapeutic approaches.




Figure 2. Approach to the asymptomatic patient with antiphospholipid antibodies. For a description, see the “How I Treat” section.

These include inhibition of intracellular signaling pathways, novel antiplatelet agents, and immunomodulatory therapies that may be especially useful in patients with recurrent thrombosis and underlying SLE. Plasma exchange, defibrotide, and complement-directed therapies have shown efficacy in case reports of catastrophic APS as well as in animal models.

Hydroxychloroquine

The antimalarial hydroxychloroquine has anti-inflammatory and immunomodulatory effects and is an established first-line treatment for SLE. It has been reported to protect against both arterial and venous thrombosis in patients with SLE, with and without APS.⁴⁸ Potential mechanisms include a decrease in lupus activity as well as modulation of APS effects. Rand et al have demonstrated that hydroxychloroquine protects the annexin A5 shield on endothelium and placental syncytiotrophoblast from disruption.⁴⁹

Hydroxychloroquine is recommended for aPL-positive patients with SLE. Hydroxychloroquine decreased aPL titers and lowered the odds of having persistently positive aPL in an observational study. Another small prospective study comparing anticoagulation with a VKA (fluidone), with or without hydroxychloroquine in patients with primary APS reported VTE in 6/20 (30%) patients in the monotherapy group but none in the hydroxychloroquine group over 36 months of follow-up.⁵⁰ There is currently no strong data to support the use of hydroxychloroquine in patients without autoimmune disorders, however, a multicenter randomized control trial of hydroxychloroquine for primary thrombosis prevention in patients with aPL without systemic autoimmune disease is currently underway (www.clinicaltrials.gov; NCT01784523).

Statins

Statins have anti-inflammatory properties and inhibit the activation of vascular cells by aPL in vitro. Simvastatin and pravastatin also inhibit aPL-induced fetal loss in a murine model.¹⁶ A small prospective study demonstrated that fluvastatin treatment for 3 months reduced the levels of inflammatory biomarkers and thrombosis in patients with aPL.⁵¹ Further clinical studies are needed to establish the role of statins as adjuvant therapy and primary thromboprophylaxis in patients with APS. Statins may be considered in patients with a history of arterial events.

How I treat asymptomatic patients with aPL

The prevalence of asymptomatic aPL in the general, healthy population has been reported to be as high as 1%-5% (although is likely lower when assessed carefully), and may be as high as 11%-86% in patients with SLE.⁶² There has been no clear benefit demonstrated for primary thromboprophylaxis of such patients. The Antiphospholipid Antibody Acetylsalicylic acid (APLASA) trial, the only randomized study addressing this question, was terminated early due to an unexpectedly low rate of thrombosis. Of the 98 participants, only 3 had a thrombotic event, all of which were in the aspirin group.⁶³ Other retrospective studies have yielded conflicting results. However, prophylaxis with LMWH or aspirin may reduce thrombotic complications in high-risk periods, such as surgery and hospitalization, and should be considered.⁶⁴ Hydroxychloroquine is recommended in patients with SLE and aPL; it reduces aPL levels and may reduce the rate of thrombosis. A recent meta-analysis concluded that primary prophylaxis with aspirin does not improve obstetric outcomes in otherwise healthy women who are asymptomatic aPL carriers.⁶⁵ Estrogen containing oral contraceptives (OCs) are clearly a risk factor for thrombosis. Although the risk of thrombosis with OCs in asymptomatic aPL carriers has not been studied, it is reasonable to assume that this combination may significantly increase thrombotic risk, and therefore alternative methods of contraception should be utilized. In a randomized trial comparing combined (estrogen containing) or progesterone-only OCs in women with SLE, only 2 of 54 patients in each group had a thrombotic event. However, all 4 of these patients were positive for aPL. The approach to asymptomatic patients with aPL is summarized in Figure 2.

B-cell directed therapy

A recent open-label, phase II trial of rituximab in primary APS reported some efficacy in controlling noncriteria manifestations, such as thrombocytopenia, hemolytic anemia, and skin ulcers.⁵² There is equivocal data supporting its use in CAPS. Twenty patients from the CAPS registry were treated with rituximab; eight (40%) received it in combination with first-line treatment because of severe presentations or associated lymphoproliferative disorders and the remainder as second-line therapy due to refractory CAPS.⁵³ Seventy-five percent of these patients recovered from the acute episode.⁵³ Other B cell-directed therapies, such as cytotoxic T lymphocyte antigen 4 (CTLA4) Ig and B-cell activating factor (BAFF), have shown efficacy in preclinical models.^{54,55}

Treatment of obstetrical APS

The treatment of obstetrical APS remains controversial, with numerous studies reporting different outcomes in similar patient populations. A recent Cochrane review concluded that aspirin alone has not been demonstrated to improve pregnancy outcomes.⁵⁶ Two prospective studies comparing aspirin with aspirin and unfractionated heparin have demonstrated an increased rate of live births in the latter group, although different doses of heparin were used.^{57,58} However, these results were not replicated in two prospective studies comparing aspirin with aspirin and LMWH due primarily to the better than expected outcomes in the aspirin alone group. Current ACCP guidelines recommend the use of low-dose aspirin with prophylactic or low-dose unfractionated or low molecular weight heparin in patients with aPL and ≥ 3 pregnancy losses.⁵⁹

Treatment of catastrophic APS

Early diagnosis and treatment of CAPS is essential in the face of a rapidly progressive, potentially fatal condition. CAPS is characterized by microvascular thrombosis, multiorgan involvement, and a systemic inflammatory response to ischemic tissue necrosis. Anticoagulation with heparin and high-dose steroids (methylprednisolone 1000 mg daily for 3 days or longer) are first-line therapy for CAPS. Plasma exchange has improved mortality in observational studies and in the CAPS registry.⁵ Intravenous immunoglobulin alone does not appear to be beneficial in patients with CAPS, but may be used with plasma exchange in patients with concomitant immune thrombocytopenia.⁵

Case reports describe the successful use of eculizumab in patients with refractory CAPS and APS-related post-renal transplant thrombotic microangiopathy.⁶⁰ The role of eculizumab in preventing recurrent CAPS after renal transplantation in patients with a prior history of CAPS is under investigation (www.clinicaltrials.gov; NCT 01029587). Eculizumab carries a risk of infection with encapsulated organisms and patients should be immunized against meningococcus before starting treatment.

Defibrotide is an adenosine receptor antagonist with antithrombotic, profibrinolytic, and anti-inflammatory effects on vascular endothelial cells that also blocks neutrophil tissue factor expression. It has been successfully used in hepatic veno-occlusive disease and multiorgan failure after stem cell transplant. Defibrotide has also been used for the treatment of refractory CAPS and is thought to act by decreasing endothelial inflammation.⁶¹

Conclusions

APS is a prothrombotic, autoimmune disorder with heterogeneous clinical presentations. Despite advances in diagnosis, correctly identifying patients at risk is a challenge. "Triple positivity" for criteria aPL is associated with the highest risk of clinical events, although of the individual assays for aPL, lupus anticoagulants are associated with the highest risk. β_2 GPI-specific LA and anti- β_2 GPI-domain I antibodies may be more sensitive markers of thrombotic risk, but are not widely available in practice. Long-term anticoagulation remains the mainstay of treatment of thrombotic APS. Innovative therapeutic approaches, such as immune modulation, complement inhibition, and targeting inflammation, are under study. Further mechanistic and clinical studies are needed to develop improved therapies for this potentially devastating illness.

Correspondence

Keith R. McCrae, Taussig Cancer Institute, R4-018, Cleveland Clinic, 9500 Euclid Ave, Cleveland, OH 44195; Phone: 216-445-7809; Fax: 216-444-9464; e-mail: mccraek@ccf.org.

References

1. Miyakis S, Lockshin MD, Atsumi T, et al. International consensus statement on an update of the classification criteria for definite antiphospholipid syndrome (APS). *J Thromb Haemost.* 2006;4(2):295-306.
2. Cervera R, Piette JC, Font J, et al. Antiphospholipid syndrome: clinical and immunologic manifestations and patterns of disease expression in a cohort of 1000 patients. *Arthritis Rheum.* 2002;46(4):1019-1027.
3. Asherson RA, Cervera R, de Groot PG, et al. Catastrophic antiphospholipid syndrome: international consensus statement on classification criteria and treatment guidelines. *Lupus.* 2003;12(7):530-534.
4. Cervera R, Serrano R, Pons-Estel GJ, et al. Morbidity and mortality in

the antiphospholipid syndrome during a 10-year period: a multicentre prospective study of 1000 patients. *Ann Rheum Dis.* 2015;74(6):1011-1018.

5. Cervera R, Espinosa G. Update on the catastrophic antiphospholipid syndrome and the "CAPS Registry". *Semin Thromb Hemost.* 2012;38(4):333-338.
6. Bucciarelli S, Espinosa G, Cervera R. The CAPS Registry: morbidity and mortality of the catastrophic antiphospholipid syndrome. *Lupus.* 2009;18(10):905-912.
7. Galli M, Borrelli G, Jacobsen EM, et al. Clinical significance of different antiphospholipid antibodies in the WAPS (warfarin in the antiphospholipid syndrome) study. *Blood.* 2007;110(4):1178-1183.
8. Bertolaccini ML, Sciascia S, Murru V, Garcia-Fernandez C, Sanna G, Khamashta MA. Prevalence of antibodies to prothrombin in solid phase (aPT) and to phosphatidylserine-prothrombin complex (aPS/PT) in patients with and without lupus anticoagulant. *Thromb Haemost.* 2013;109(2):207-213.
9. Iverson GM, Victoria EJ, Marquis DM. Anti-beta2 glycoprotein I (beta2GPI) autoantibodies recognize an epitope on the first domain of beta2GPI. *Proc Natl Acad Sci U S A.* 1998;95(26):15542-15546.
10. Agar C, van Os GM, Morgelin M, et al. Beta2-glycoprotein I can exist in 2 conformations: implications for our understanding of the antiphospholipid syndrome. *Blood.* 2010;116(8):1336-1343.
11. McNeil HP, Simpson RJ, Chesterman CN, Krilis SA. Anti-phospholipid antibodies are directed against a complex antigen that includes a lipid-binding inhibitor of coagulation: beta 2-glycoprotein I (apolipoprotein H). *Proc Natl Acad Sci U S A.* 1990;87(11):4120-4124.
12. Devreese K, Peerlinck K, Hoylaerts MF. Thrombotic risk assessment in the antiphospholipid syndrome requires more than the quantification of lupus anticoagulants. *Blood.* 2010;115(4):870-878.
13. Rand JH, Wu XX, Lapinski R, et al. Detection of antibody-mediated reduction of annexin A5 anticoagulant activity in plasmas of patients with the antiphospholipid syndrome. *Blood.* 2004;104(9):2783-2790.
14. Hulstein JJ, Lenting PJ, de Laat B, Derksen RH, Fijnheer R, de Groot PG. beta2-Glycoprotein I inhibits von Willebrand factor dependent platelet adhesion and aggregation. *Blood.* 2007;110(5):1483-1491.
15. Giannakopoulos B, Krilis SA. The pathogenesis of the antiphospholipid syndrome. *N Engl J Med.* 2013;368(11):1033-1044.
16. Redecha P, Franke CW, Ruf W, Mackman N, Girardi G. Neutrophil activation by the tissue factor/Factor VIIa/PAR2 axis mediates fetal death in a mouse model of antiphospholipid syndrome. *J Clin Invest.* 2008;118(10):3453-3461.
17. Pengo V, Tripodi A, Reber G, et al. Update of the guidelines for lupus anticoagulant detection: Subcommittee on Lupus Anticoagulant/Antiphospholipid Antibody of the Scientific and Standardisation Committee of the International Society on Thrombosis and Haemostasis. *J Thromb Haemost.* 2009;7(10):1737-1740.
18. Willis R, Lakos G, Harris EN. Standardization of antiphospholipid antibody testing—historical perspectives and ongoing initiatives. *Semin Thromb Hemost.* 2014;40(2):172-177.
19. Merriman E, Kaplan Z, Butler J, Malan E, Gan E, Tran H. Rivaroxaban and false positive lupus anticoagulant testing. *Thromb Haemost.* 2011;105(2):385-386.
20. Tripodi A, Chantarangkul V, Clerici M, Mannucci PM. Laboratory diagnosis of lupus anticoagulants for patients on oral anticoagulant treatment: performance of dilute Russell viper venom test and silica clotting time in comparison with Staclot LA. *Thromb Haemost.* 2002;88(4):583-586.
21. Martinuzzo ME, Barrera LH, MA Da, Otaso JC, Gimenez MI, Oyhamburu J. Frequent false-positive results of lupus anticoagulant tests in plasmas of patients receiving the new oral anticoagulants and enoxaparin. *Int J Lab Hematol.* 2014;36(2):144-150.
22. Moore GW. Recent guidelines and recommendations for laboratory detection of lupus anticoagulants. *Semin Thromb Hemost.* 2014;40(2):163-171.
23. Parmar K, Lefkou E, Doughty H, Connor P, Hunt BJ. The utility of the Taipan snake venom assay in assessing lupus anticoagulant status in

- individuals receiving or not receiving an oral vitamin K antagonist. *Blood Coagul Fibrinolysis*. 2009;20(4):271-275.
24. van Os GM, de Laat B, Kamphuisen PW, Meijers JC, de Groot PG. Detection of lupus anticoagulant in the presence of rivaroxaban using Taipan snake venom time. *J Thromb Haemost*. 2011;9(8):1657-1659.
 25. De Laat B, Derksen RH, Reber G, et al. An international multicentre-laboratory evaluation of a new assay to detect specifically lupus anticoagulants dependent on the presence of anti-beta2-glycoprotein autoantibodies. *J Thromb Haemost*. 2011;9(1):149-153.
 26. de Laat HB, Derksen RH, Urbanus RT, Roest M, de Groot PG. beta2-glycoprotein I-dependent lupus anticoagulant highly correlates with thrombosis in the antiphospholipid syndrome. *Blood*. 2004;104(12):3598-3602.
 27. Urbanus RT, Siegerink B, Roest M, Rosendaal FR, de Groot PG, Algra A. Antiphospholipid antibodies and risk of myocardial infarction and ischaemic stroke in young women in the RATIO study: a case-control study. *Lancet Neurol*. 2009;8(11):998-1005.
 28. Urbanus RT, de Groot PG. Antiphospholipid antibodies: we are not quite there yet. *Blood Rev*. 2011;25(2):97-106.
 29. Devreese K, Hoylaerts MF. Challenges in the diagnosis of the antiphospholipid syndrome. *Clin Chem*. 2010;56(6):930-940.
 30. de Groot PG, Lutters B, Derksen RH, Lisman T, Meijers JC, Rosendaal FR. Lupus anticoagulants and the risk of a first episode of deep venous thrombosis. *J Thromb Haemost*. 2005;3(9):1993-1997.
 31. Pengo V, Ruffatti A, Legnani C, et al. Clinical course of high-risk patients diagnosed with antiphospholipid syndrome. *J Thromb Haemost*. 2010;8(2):237-242.
 32. Mustonen P, Lehtonen KV, Javela K, Puurunen M. Persistent antiphospholipid antibody (aPL) in asymptomatic carriers as a risk factor for future thrombotic events: a nationwide prospective study. *Lupus*. 2014;23(14):1468-1476.
 33. de Laat B, Derksen RH, Urbanus RT, de Groot PG. IgG antibodies that recognize epitope Gly40-Arg43 in domain I of beta 2-glycoprotein I cause LAC, and their presence correlates strongly with thrombosis. *Blood*. 2005;105(4):1540-1545.
 34. de Laat B, Pengo V, Pabinger I, et al. The association between circulating antibodies against domain I of beta2-glycoprotein I and thrombosis: an international multicenter study. *J Thromb Haemost*. 2009;7(11):1767-1773.
 35. Pengo V, Ruffatti A, Tonello M, et al. Antiphospholipid syndrome: antibodies to Domain I of beta2-glycoprotein I correctly classify patients at risk. *J Thromb Haemost*. 2015;13(5):782-787.
 36. Clark CA, Davidovits J, Spitzer KA, Laskin CA. The lupus anticoagulant: results from 2257 patients attending a high-risk pregnancy clinic. *Blood*. 2013;122(3):341-347; quiz 466.
 37. Lockshin MD, Kim M, Laskin CA, et al. Prediction of adverse pregnancy outcome by the presence of lupus anticoagulant, but not anticardiolipin antibody, in patients with antiphospholipid antibodies. *Arthritis Rheum*. 2012;64(7):2311-2318.
 38. Chaleur C, Galanaud JP, Alonso S, et al. Observational study of pregnant women with a previous spontaneous abortion before the 10th gestation week with and without antiphospholipid antibodies. *J Thromb Haemost*. 2010;8(4):699-706.
 39. Crowther MA, Ginsberg JS, Julian J, et al. A comparison of two intensities of warfarin for the prevention of recurrent thrombosis in patients with the antiphospholipid antibody syndrome. *N Engl J Med*. 2003;349(12):1133-1138.
 40. Finazzi G, Marchioli R, Brancaccio V, et al. A randomized clinical trial of high-intensity warfarin vs. conventional antithrombotic therapy for the prevention of recurrent thrombosis in patients with the antiphospholipid syndrome (WAPS). *J Thromb Haemost*. 2005;3(5):848-853.
 41. Garcia D, Akl EA, Carr R, Kearon C. Antiphospholipid antibodies and the risk of recurrence after a first episode of venous thromboembolism: a systematic review. *Blood*. 2013;122(5):817-824.
 42. Hunt BJ. Pediatric antiphospholipid antibodies and antiphospholipid syndrome. *Semin Thromb Hemost*. 2008;34(3):274-281.
 43. Levine SR, Brey RL, Tilley BC, et al. Antiphospholipid antibodies and subsequent thrombo-occlusive events in patients with ischemic stroke. *JAMA*. 2004;291(5):576-584.
 44. Okuma H, Kitagawa Y, Yasuda T, Tokuoka K, Takagi S. Comparison between single antiplatelet therapy and combination of antiplatelet and anticoagulation therapy for secondary prevention in ischemic stroke patients with antiphospholipid syndrome. *Int J Med Sci*. 2009;7(1):15-18.
 45. Son M, Wypasek E, Celinska-Lowenhoff M, Undas A. The use of rivaroxaban in patients with antiphospholipid syndrome: a series of 12 cases. *Thromb Res*. 2015;135(5):1035-1036.
 46. Schaefer JK, McBane RD, Black DF, Williams LN, Moder KG, Wysokinski WE. Failure of dabigatran and rivaroxaban to prevent thromboembolism in antiphospholipid syndrome: a case series of three patients. *Thromb Haemost*. 2014;112(5):947-950.
 47. Win K, Rodgers GM. New oral anticoagulants may not be effective to prevent venous thromboembolism in patients with antiphospholipid syndrome. *Am J Hematol*. 2014;89(10):1017.
 48. Petri M. Use of hydroxychloroquine to prevent thrombosis in systemic lupus erythematosus and in antiphospholipid antibody-positive patients. *Curr Rheumatol Rep*. 2011;13(1):77-80.
 49. Wu XX, Guller S, Rand JH. Hydroxychloroquine reduces binding of antiphospholipid antibodies to syncytiotrophoblasts and restores annexin A5 expression. *Am J Obstet Gynecol*. 2011;205(6):576.e577-514.
 50. Schmidt-Tanguy A, Voswinkel J, Henrion D, et al. Antithrombotic effects of hydroxychloroquine in primary antiphospholipid syndrome patients. *J Thromb Haemost*. 2013;11(10):1927-1929.
 51. Erkan D, Willis R, Murthy VL, et al. A prospective open-label pilot study of fluvastatin on proinflammatory and prothrombotic biomarkers in antiphospholipid antibody positive patients. *Ann Rheum Dis*. 2014;73(6):1176-1180.
 52. Erkan D, Vega J, Ramon G, Kozora E, Lockshin MD. A pilot open-label phase II trial of rituximab for non-criteria manifestations of antiphospholipid syndrome. *Arthritis Rheum*. 2013;65(2):464-471.
 53. Berman H, Rodriguez-Pinto I, Cervera R, et al. Rituximab use in the catastrophic antiphospholipid syndrome: descriptive analysis of the CAPS registry patients receiving rituximab. *Autoimmun Rev*. 2013;12(11):1085-1090.
 54. Kim KS, Denton MD, Chandraker A, et al. CD28-B7-mediated T cell costimulation in chronic cardiac allograft rejection: differential role of B7-1 in initiation versus progression of graft arteriosclerosis. *Am J Pathol*. 2001;158(3):977-986.
 55. Kahn P, Ramanujam M, Bethunaickan R, et al. Prevention of murine antiphospholipid syndrome by BAFF blockade. *Arthritis Rheum*. 2008;58(9):2824-2834.
 56. Empson M, Lassere M, Craig J, Scott J. Prevention of recurrent miscarriage for women with antiphospholipid antibody or lupus anticoagulant. *Cochrane Database Syst Rev*. 2005(2):Cd002859.
 57. Backos M, Rai R, Baxter N, Chilcott IT, Cohen H, Regan L. Pregnancy complications in women with recurrent miscarriage associated with antiphospholipid antibodies treated with low dose aspirin and heparin. *Br J Obstet Gynaecol*. 1999;106(2):102-107.
 58. Rai R, Cohen H, Dave M, Regan L. Randomised controlled trial of aspirin and aspirin plus heparin in pregnant women with recurrent miscarriage associated with phospholipid antibodies (or antiphospholipid antibodies). *BMJ*. 1997;314(7076):253-257.
 59. Bates SM, Greer IA, Middeldorp S, Veenstra DL, Prabulos AM, Vandvik PO. VTE, thrombophilia, antithrombotic therapy, and pregnancy: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. *Chest*. 2012;141(Suppl 2):e691S-736S.
 60. Lonze BE, Zachary AA, Magro CM, et al. Eculizumab prevents recurrent antiphospholipid antibody syndrome and enables successful renal transplantation. *Am J Transplant*. 2014;14(2):459-465.
 61. Burcoglu-O'Ral A, Erkan D, Asherson R. Treatment of catastrophic antiphospholipid syndrome with defibrotide, a proposed vascular endothelial cell modulator. *J Rheumatol*. 2002;29(9):2006-2011.
 62. Petri M. Epidemiology of the antiphospholipid antibody syndrome. *J Autoimmun*. 2000;15(2):145-151.

63. Erkan D, Harrison MJ, Levy R, et al. Aspirin for primary thrombosis prevention in the antiphospholipid syndrome: a randomized, double-blind, placebo-controlled trial in asymptomatic antiphospholipid antibody-positive individuals. *Arthritis Rheum.* 2007;56(7):2382-2391.
64. Giron-Gonzalez JA, Garcia del Rio E, Rodriguez C, Rodriguez-Martorell J, Serrano A. Antiphospholipid syndrome and asymptomatic carriers of antiphospholipid antibody: prospective analysis of 404 individuals. *J Rheumatol.* 2004;31(8):1560-1567.
65. Amengual O, Fujita D, Ota E, et al. Primary prophylaxis to prevent obstetric complications in asymptomatic women with antiphospholipid antibodies: a systematic review. *Lupus.* 2015;24(11):1135-1142.